Kindred Biosciences to Participate in Stifel Virtual Healthcare Conference and A.G.P. Virtual Healthcare Symposium

SAN FRANCISCO, November 11, 2020 — Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, will present at the Stifel Virtual Healthcare Conference on November 17 and participate in the A.G.P. Virtual Healthcare Symposium on November 19. Dr. Richard Chin, Chief Executive Officer, will be available for one-on-one meetings. During […]

Kindred Biosciences Announces Third Quarter 2020 Financial Results

San Francisco, California (November 9, 2020) – Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced financial results for the third quarter ended September 30, 2020 and provided updates on its programs. For the third quarter of 2020, KindredBio reported net revenues of $1.0 million […]

Kindred Biosciences to Announce Third Quarter 2020 Financial Results

Company to Hold Conference Call and Webcast at 4:30 p.m. Eastern Time/1:30 p.m. Pacific Time on Monday, November 9, 2020. San Francisco, California (October 28, 2020) — Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, will release its third quarter 2020 financial results on November 9, […]

Kindred Biosciences Announces Expansion of Manufacturing Agreement with Vaxart for COVID-19 and Other Vaccine Candidates

San Francisco, California (October 7, 2020) – Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company developing novel biologics, today announced it has expanded an agreement with Vaxart, Inc. (Nasdaq: VXRT) for the manufacture of Vaxart’s oral vaccine for COVID-19 and other vaccine candidates. The manufacturing services will be performed via Centaur Biopharmaceutical Services (Centaur), a […]

Kindred Biosciences Announces Positive Results from Pivotal Efficacy Study of Parvovirus Monoclonal Antibody

Study demonstrated 100% efficacy in prevention of parvovirus infection in prophylactic pivotal study of KIND-030 San Francisco, California (September 16, 2020) – Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced positive results from a pivotal efficacy study of KIND-030, a monoclonal antibody targeting canine […]